Amyloid heart disease

British Journal of Hospital Medicine

Volumn 71, Issue 2, 2010, Pages 76-82

  Dubrcy, Simon W ^a   Falk, Rodney H ^b  

^a HILLINGDON HOSPITAL   (United Kingdom)

^b HARVARD VANGUARD MEDICAL ASSOCIATES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; PREALBUMIN;

AMYLOIDOSIS; ARTICLE; ECHOGRAPHY; EPIDEMIOLOGY; HEART DISEASE; HEART TRANSPLANTATION; HUMAN; METABOLISM; PROGNOSIS; RISK FACTOR; STEM CELL TRANSPLANTATION; TIME;

AMYLOID; AMYLOIDOSIS; EPIDEMIOLOGIC METHODS; HEART DISEASES; HEART TRANSPLANTATION; HUMANS; PREALBUMIN; PROGNOSIS; RISK FACTORS; STEM CELL TRANSPLANTATION; TIME FACTORS;

EID: 77952297474     PISSN: 17508460     EISSN: None     Source Type: Journal    
DOI: 10.12968/hmed.2010.71.2.46484     Document Type: Conference Paper

References (33)

1. Bergstrom J, Gustavsson A, Hellman U et al (2005) Amyloid deposits in transthyretin-derived amyloidosis: cleaved transthyretin is associated with distinct amyloid morphology. J Pathol 206(2): 224 - 32.
2. Comenzo RL, Vosburgh E, Falk RH et al (1998) Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light chain) amyloidosis: survival and responses in 25 patients. Blood 91(10): 3662-70.
3. Dispenzieri A, Lacy MQ, Rajkumar SV et al (2003) Poor tolerance to high doses of thalidomide in subjects with primary systemic amyloidosis. Amyloid 10(4): 257-61.
4. Dubrey SW, Cha K, Simms RW, Skinner M, Falk RH (1996) Electrocardiography and Doppler echocardiography in secondary (AA) amyloidosis. Am J Cardial 77 (4): 313- 15.
5. Dubrey SW, Davidoff R, Skinner M, Bergethon P, Lewis D, Falk RH (1997) Progression of ventricular wall thickening after liver transplantation for familial amyloidosis. Transplant 64: 74-80. (Pubitemid 27327203)
6. Dubrey SW, Burke MM, Hawkins PN, Banner NR (2004) Cardiac transplantation for amyloid heart disease - the United Kingdom experience, J Heart Lung Transplant 23(10): 1142-53.
7. Gertz MA, Lacy MQ, Dispenzieri A et al (2002) A multicenter phase II trial of 4'-iodo-4'deoxydoxorubicin (IDOX) in primary amyloidosis (AL). Amyloid 9(1): 24-30.
8. Gianni L, Bellotti V, Gianni AM, Merlini G (1995) New drug therapy of amyloidosis: resorption of AL-type deposits with 4'-iodo- 4'deoxydoKombidn. Blood 86(3): 855-61.
9. Gillmore JD, Goodman HJ, Lachmann HJ et al (2006) Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood 107(3): 1227-9.
10. Guidelines Working Group of UK Myeloma Forum; British Commitee for Standards in Haematology, British Society for Haematology (2004) Guidelines on the diagnosis and management of AL amyloidoisis. Br J Haematol 125(6): 681-700.
11. Hawkins PN, Lavender JP, Pepys MB (1990) Evaluation of systemic amyloidosis by scintigraphy with labelled 1231-labelled serum amyloid P component. N Engl J Med 323: 508-13.
12. Holmgren G, Ericzon BG, Groth CG et al (1993) Clinical improvement and amyloid regression alter liver transplantation in hereditary transthyretin amyloidosis. Lancet 341: 1113-16.
13. Hosenpud JD, DeMarco T, Frazier H et al (1991) Progression of systemic disease and reduced long term survival in patients with cardiac amyloidosis undergoing heart transplantation. Circulation 84(III): 338-43.
14. Jaccard A, Moreau P, Leblond V et al (2007) High dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 357: 1083-93.
15. Kawamura S, Takahashi M, Ishihara T, Uchino F (1995) Incidence and distribution of isolated atrial amyloid: histologic and immunohistochemical studies of 100 aging hearts. Pathol Int 45(5): 335-42.
16. Koyama J, Ray-Sequin PA, Davidoff R, Falk RH (2002) Usefulness of pulsed tissue Doppler imaging for evaluating systolic and diastolic left ventricular dysfunction in patients with AL (primary) amyloidosis. Am J Cardial 89(9): 1067-71.
17. Lachmann HJ, Booth DR, Booth SE et al (2002) Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 346: 1786-91.
18. Lachmann HJ, Gallimore R, Gillmore JD et al (2003) Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 122(1): 78-84.
19. Lacy MQ, Dispenzieri A, Hayman SR et al (2008) Autologous stem cell transplant after heart transplant for light chain (AL) amyloid cardiomyopathy. J Heart Lung Tramplant 27(8): 823-9.
20. Liao R, Jain M, Teller P et al (2001) Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 104(14): 1594-7.
21. Maceira AM, Joshi J, Prasad SK (2005) Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 111: 195-202.
22. Maurer MS, Raina A, Hesdorffer C et al (2007) Cardiac transplantation using extended-donor criteria organs tor systemic amyloidosis complicated by heart failure. Transplantation 83(5): 539-45.
23. Miller SR, Sekijima Y, Kelly JW (2004) Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest 84(5): 545-52.
24. Mollee PN, Wechalekar AD, Pereira DL et al (2004) Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome. Bone Marrow Transplant 33(3): 271-7.
25. Oza VB, Smith C, Raman P et al (2002) Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors.J Med Chem 45(2): 321-32.
26. Palladini G, Perfetti V, Pedini S et al (2005) The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 105(7): 2949-51.
27. Sack FU, Kristen A, Goldschmidt H et al (2008) Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidos. Fur J Cardiothorac Surg 33: 257-62.
28. Sanchorawala V, Seldin DC, Magnani B, Skinner M, Wright DG (2005) Serum free light chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplant 36(7): 597-600.
29. Sekijima Y, Dendle MA, Kelly JW (2006) Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid 13(4): 236-49.
30. Seldin DC, Choufani EB, Dember LM et al (2003) Tolerability and efficacy of thalidomide for the treatment of subjects with light chain-associated (AL) amyloidosis. Clin Lymphoma 3(4): 241-6.
31. Skinner M, Sanchorawala V, Seldin DC et al (2004) High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8 year study. Ann Int Med 140: 85-93.
32. Yazaki M, Tokuda T, Nakamura A et al (2000) Cardiac amyloid in patients with familial amyloid polyneuropathy consists of abundant wild-type transthyretin. Biochem Biophys Res Comms 274(3): 702-6.
33. Zeldenrust S, Gertz M, Uemichi T et al (2003) Orthotopic liver transplantation for hereditary fibrinogen amyloidosis. Transplantation 75: 560-1.